Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(14)
•••
Post by PhillUpBankson Jun 10, 2020 1:04am
472 Views
Post# 31131864

The way observe the situation...

The way observe the situation...You have Wallace who's legacy is in what he just accomplished. Then The new CMO who is experienced knows what is needed from the FDA. And Legault who now has a billion dollar(plus more) gem in his hands. No decision is made without consultation from the 3 individuals at this point.  I believe they are taking the necessary steps (with caution) to achieve the best outcome as their careers can be cemented with this company.. as a partial owner of Antibe all I can do is trust in them because I am pretty sure they have more knowledge and insight then anyone on this bullboard because if the people on this board yapping had an idea they would be on the other of this scenario instead of on stockhouse with me... do your own due diligence and make your own risk assessment and believe in your judgement. And if you do not own a piece of this company WHY ARE YOU HERE?? A lot of new faces since the results and to be honest nobody is credible except a few( mstrmind, Mugz, qwerty and a few others) I don't post often but I read everything.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities